Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
First of its kind screening for Glaucoma at grass root level over 10k screened already
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Subscribe To Our Newsletter & Stay Updated